Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome
- 31 October 2005
- journal article
- research article
- Published by Elsevier in Leukemia Research
- Vol. 29 (10) , 1217-1219
- https://doi.org/10.1016/j.leukres.2005.03.004
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Darbepoetin alpha for the treatment of anaemia in low‐intermediate risk myelodysplastic syndromesBritish Journal of Haematology, 2004
- Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the united states and other countriesThe American Journal of Medicine, 2004
- Use of Epoetin in Patients With Cancer: Evidence-Based Clinical Practice Guidelines of the American Society of Clinical Oncology and the American Society of HematologyJournal of Clinical Oncology, 2002
- More Concern About Transfusion Requirement When Evaluating Quality of Life in Anemic PatientsJournal of Clinical Oncology, 2002
- Anemia, Transfusion, and MortalityNew England Journal of Medicine, 2001
- Pathophysiology of anaemia: focus on the heart and blood vesselsNephrology Dialysis Transplantation, 2000
- Effect of growth on variability of left ventricular mass: Assessment of allometric signals in adults and children and their capacity to predict cardiovascular riskJournal of the American College of Cardiology, 1995